ASCO® 2022

Presentations

Brentuximab Vedotin | DLBCL | Abstract #7559

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study

View/Download

Brentuximab Vedotin | cHL | Abstract #7503

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1

View/Download